PLBD2

Across TCGA pan-cancer cohorts, PLBD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLBD2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PLBD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLBD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

COAD, LUAD, and GBM are the cancer types where PLBD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.907	1.000	.038	24	view →
LUAD	OS	Tertile	All	0.465	0.817	.009	10	view →
GBM	OS	Tertile	All	0.395	0.668	.012	7	view →
HNSC	OS	Quartile	IV	0.509	0.827	.016	7	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.900	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLBD2–COAD (DFS)

Open the COAD breakdown →